{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T06:27:56Z","timestamp":1657088876977},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,5,13]],"date-time":"2019-05-13T00:00:00Z","timestamp":1557705600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,5,13]],"date-time":"2019-05-13T00:00:00Z","timestamp":1557705600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Herz"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s00059-019-4811-x","type":"journal-article","created":{"date-parts":[[2019,5,14]],"date-time":"2019-05-14T03:22:53Z","timestamp":1557804173000},"page":"365-378","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Orale Antikoagulation und antithrombozyt\u00e4re Therapie bei Patienten mit Vorhofflimmern nach Koronarintervention"],"prefix":"10.1007","volume":"44","author":[{"given":"A.","family":"Sch\u00e4fer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Bauersachs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,5,13]]},"reference":[{"key":"4811_CR1","doi-asserted-by":"publisher","first-page":"2864","DOI":"10.1001\/jama.285.22.2864","volume":"285","author":"BF Gage","year":"2001","unstructured":"Gage BF, Waterman AD, Shannon W et\u00a0al (2001) Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 285:2864\u20132870","journal-title":"JAMA"},{"key":"4811_CR2","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1378\/chest.09-1584","volume":"137","author":"GY Lip","year":"2010","unstructured":"Lip GY, Nieuwlaat R, Pisters R et al (2010) Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a\u00a0novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 137:263\u2013272","journal-title":"Chest"},{"key":"4811_CR3","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1056\/NEJM199309023291001","volume":"329","author":"G Investigators","year":"1993","unstructured":"Investigators G (1993) An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N\u00a0Engl J Med 329:673\u2013682","journal-title":"N Engl J Med"},{"key":"4811_CR4","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1378\/chest.10-0134","volume":"138","author":"R Pisters","year":"2010","unstructured":"Pisters R, Lane DA, Nieuwlaat R et al (2010) A novel user-friendly score (HAS-BLED) to assess 1\u2011year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 138:1093\u20131100","journal-title":"Chest"},{"key":"4811_CR5","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"S Schulman","year":"2005","unstructured":"Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the ISTH (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J\u00a0Thromb Haemost 3:692\u2013694","journal-title":"J Thromb Haemost"},{"key":"4811_CR6","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/S0140-6736(17)30397-5","volume":"389","author":"F Costa","year":"2017","unstructured":"Costa F, Van Klaveren D, James S et al (2017) Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a\u00a0pooled analysis of individual-patient datasets from clinical trials. Lancet 389:1025\u20131034","journal-title":"Lancet"},{"key":"4811_CR7","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1161\/01.CIR.76.1.142","volume":"76","author":"JH Chesebro","year":"1987","unstructured":"Chesebro JH, Knatterud G, Roberts R et\u00a0al (1987) Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation 76:142\u2013154","journal-title":"Circulation"},{"key":"4811_CR8","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1056\/NEJM199604253341702","volume":"334","author":"A Schomig","year":"1996","unstructured":"Schomig A, Neumann FJ, Kastrati A et al (1996) A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N\u00a0Engl J Med 334:1084\u20131089","journal-title":"N Engl J Med"},{"key":"4811_CR9","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","volume":"37","author":"P Kirchhof","year":"2016","unstructured":"Kirchhof P, Benussi S, Kotecha D et\u00a0al (2016) 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart\u00a0J 37:2893\u20132962","journal-title":"Eur Heart J"},{"key":"4811_CR10","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1056\/NEJM199812033392303","volume":"339","author":"MB Leon","year":"1998","unstructured":"Leon MB, Baim DS, Popma JJ et al (1998) A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N\u00a0Engl J Med 339:1665\u20131671","journal-title":"N Engl J Med"},{"key":"4811_CR11","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1016\/S0140-6736(06)68845-4","volume":"367","author":"S Connolly","year":"2006","unstructured":"Investigators AWGOTA, Connolly S, Pogue J et\u00a0al (2006) Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a\u00a0randomised controlled trial. Lancet 367:1903\u20131912","journal-title":"Lancet"},{"key":"4811_CR12","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1001\/archinternmed.2010.271","volume":"170","author":"ML Hansen","year":"2010","unstructured":"Hansen ML, Sorensen R, Clausen MT et\u00a0al (2010) Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med 170:1433\u20131441","journal-title":"Arch Intern Med"},{"key":"4811_CR13","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1016\/S0140-6736(09)61751-7","volume":"374","author":"R Sorensen","year":"2009","unstructured":"Sorensen R, Hansen ML, Abildstrom SZ et\u00a0al (2009) Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a\u00a0retrospective analysis of nationwide registry data. Lancet 374:1967\u20131974","journal-title":"Lancet"},{"key":"4811_CR14","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1378\/chest.09-3083","volume":"139","author":"HJ Zhao","year":"2011","unstructured":"Zhao HJ, Zheng ZT, Wang ZH et al (2011) \u201cTriple therapy\u201d rather than \u201ctriple threat\u201d: a\u00a0meta-analysis of the two antithrombotic regimens after stent implantation in patients receiving long-term oral anticoagulant treatment. Chest 139:260\u2013270","journal-title":"Chest"},{"key":"4811_CR15","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1007\/s00059-017-4634-6","volume":"42","author":"A Sch\u00e4fer","year":"2017","unstructured":"Sch\u00e4fer A, Bauersachs J (2017) Focused update on dual antiplatelet treatment : ESC guidelines 2017. Herz 42:739\u2013745","journal-title":"Herz"},{"key":"4811_CR16","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","volume":"39","author":"M Valgimigli","year":"2018","unstructured":"Valgimigli M, Bueno H, Byrne RA et\u00a0al (2018) 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur Heart\u00a0J 39:213\u2013260","journal-title":"Eur Heart J"},{"key":"4811_CR17","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/eurheartj\/ehy394","volume":"40","author":"FJ Neumann","year":"2019","unstructured":"Neumann FJ, Sousa-Uva M, Ahlsson A et al (2019) 2018 ESC\/EACTS Guidelines on myocardial revascularization. Eur Heart\u00a0J 40:87\u2013165","journal-title":"Eur Heart J"},{"key":"4811_CR18","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","volume":"381","author":"WJ Dewilde","year":"2013","unstructured":"Dewilde WJ, Oirbans T, Verheugt FW et al (2013) Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 381:1107\u20131115","journal-title":"Lancet"},{"key":"4811_CR19","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","volume":"375","author":"CM Gibson","year":"2016","unstructured":"Gibson CM, Mehran R, Bode C et\u00a0al (2016) Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N\u00a0Engl J Med 375:2423\u20132434","journal-title":"N Engl J Med"},{"key":"4811_CR20","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","volume":"377","author":"CP Cannon","year":"2017","unstructured":"Cannon CP, Bhatt DL, Oldgren J et\u00a0al (2017) Dual Antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N\u00a0Engl J Med 377:1513\u20131524","journal-title":"N Engl J Med"},{"key":"4811_CR21","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","volume":"380","author":"RD Lopes","year":"2019","unstructured":"Lopes RD, Heizer G, Aronson R et\u00a0al (2019) Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N\u00a0Engl J Med 380:1509\u20131524. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1817083","journal-title":"N\u00a0Engl J Med"},{"key":"4811_CR22","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1007\/s00059-017-4657-z","volume":"43","author":"A Schafer","year":"2018","unstructured":"Schafer A, Bauersachs J (2018) Platelet inhibition in elderly patients. Herz 43:222\u2013229","journal-title":"Herz"},{"key":"4811_CR23","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, Mcmurray JJ et\u00a0al (2011) Apixaban versus warfarin in patients with atrial fibrillation. N\u00a0Engl J Med 365:981\u2013992","journal-title":"N Engl J Med"},{"key":"4811_CR24","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.ahj.2017.10.009","volume":"196","author":"P Vranckx","year":"2018","unstructured":"Vranckx P, Lewalter T, Valgimigli M et al (2018) Evaluation of the safety and efficacy of an edoxaban-based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention (PCI) with stent placement: Rationale and design of the ENTRUST-AF PCI trial. Am Heart\u00a0J 196:105\u2013112","journal-title":"Am Heart J"}],"container-title":["Herz"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-019-4811-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00059-019-4811-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-019-4811-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T23:20:20Z","timestamp":1589239220000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00059-019-4811-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,13]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["4811"],"URL":"https:\/\/doi.org\/10.1007\/s00059-019-4811-x","relation":{},"ISSN":["0340-9937","1615-6692"],"issn-type":[{"value":"0340-9937","type":"print"},{"value":"1615-6692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,13]]},"assertion":[{"value":"13 May 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"A.\u00a0Sch\u00e4fer und J.\u00a0Bauersachs erhielten Vortrags-\/Beratungshonorare von Boehringer Ingelheim, Bayer, BMS, Pfizer und Daiichi-Sankyo.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}